EUCTR2021-002027-38-ES进行中（未招募）1 期
A Phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer - HARMONIA trial - HARMONIA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- SOLTI
- 入组人数
- 516
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male/female patients =18 years of age
- •2. HR-positive and HER2-negative breast cancer by local testing
- •3. ECOG performance status of 0 to 1.
- •4. Patient has advanced (loco regionally recurrent not amenable to curative therapy or metastatic) breast cancer.
- •5. Availability of FFPE tumor block for biomarker analysis, obtained during metastatic period.
- •6. HER2-E or Basal-like subtype as per central PAM50 analysis.
- •7. Measurable disease or non-measurable (but evaluable), as defined by RECIST v1.1.
- •8. Adequate hematologic and end-organ function
- •9. Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures.
- •10. Women of childbearing potential must have confirmed negative serum pregnancy test.
- •11. Women of CBP must be willing to use highly effective methods of contraception.
- •12. Postmenopausal OR Pre/perimenopausal status as defined in protocol
- •13. Patients must have the ability to swallow oral medication.
- •14. Patient must have a 6-lead or 12-lead ECG at screening
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 500
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 16
排除标准
- •1. Prior therapy with any CDK4/6 inhibitors.
- •2. Patient has received prior treatment with chemotherapy for advanced / metastatic breast cancer (neoadjuvant/ adjuvant chemotherapy for early breast cancer is allowed).
- •3. Patient has received extended-field radiotherapy = 4 weeks or limited field radiotherapy = 2 weeks prior to enrollment and has not recovered to grade 1 or better from related side effects of such therapy. Patients in whom = 25% of the bone marrow has been previously irradiated are also excluded[60].
- •4. Any ongoing acute toxic effects of prior anti-cancer therapy or major surgical procedures to NCI CTCAE version 4.03 Grade = 1 at day of inclusion.
- •5. Uncontrolled pleural effusion, pericardial effusion, or ascites.
- •6. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
- •7. Known active central nervous system metastases and/or carcinomatous meningitis.
- •8. Known history of Human Immunodeficiency Virus (HIV).
- •9. Patient has known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
- •10. Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality
- •11. Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol or limit life expectancy to =6 months.
- •12. Participation in other studies involving investigational drug(s) within 30 days prior to randomization or within 5 half-lives of the investigational drug(s)
- •13. Pregnant or breast-feeding women or women who plan to become pregnant or breast-feed during the trial.
- •14. Not able to understand and to comply with study instructions and requirements according to investigator criteria.
- •For HER2-E cohort only:
- •15. Patient with a known hypersensitivity to any of the excipients of ribociclib, palbociclib and/or endocrine therapy
- •16. Patient is currently receiving any protocol-prohibited substances within 7 days before randomization
- •17. Patient is currently receiving or has received systemic corticosteroids = 2 weeks prior to starting trial treatment, or has not fully recovered from side effects of such treatment.
- •18. Patient has impairment of GI function or GI disease that may significantly alter the absorption of the oral trial treatments
- •For Basal-like cohort only:
- •19. History of hypersensitivity reactions to paclitaxel or other drugs formulated in the same solvent as paclitaxel (polyoxyethylated castor oil)
研究者
相似试验
进行中（未招募）
1 期
Comparative study of ribociclib and palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer - HARMONIA trialEUCTR2021-002027-38-PTSOLTI306
进行中（未招募）
3 期
A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistaminesChronic Spontaneous UrticariaBTK inhibitorJPRN-jRCT2061210066Hiroyuki Yamada70
进行中（未招募）
不适用
A multicentre, open label Phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant of other systemic therapies including cyclosporin, methotrexate and PUVA. - efalizumab physician experience studyAdult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporin, methotrexate and PUVAMedDRA version: 7.0Level: PTClassification code 10037153EUCTR2004-001236-23-ATSerono International S.A.1,500
进行中（未招募）
不适用
A multicentre, open label Phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporin, methotrexate and PUVA. - efalizumab physician experience studyAdult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant of other systemic therapies including cyclosporin, methotrexate and PUVAMedDRA version: 7.0Level: PTClassification code 10037153EUCTR2004-001236-23-DKSerono International S.A.1,500
进行中（未招募）
不适用
A multicentre, open label Phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporin, methotrexate and PUVA. - efalizumab physician experience studyEUCTR2004-001236-23-FISerono International S.A.1,500